RxDoctor Payments Data

Susan Frick

Optometrist · Jacksonville, FLNPI 1649406943

Payments from drug & device makers

$3,021in general payments, 2019–2025

Across 100 payments — averaging $30.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$628
  • Bausch & Lomb Americas Inc.$514
  • Johnson & Johnson Vision Care, Inc.$352
  • Sun Pharmaceutical Industries Inc.$277
  • Johnson & Johnson Surgical Vision, Inc.$170
  • Kala Pharmaceuticals, Inc.$165
  • plus $916 from 15 others

What the payments were for

  • Food & beverage$3,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,021 in reported general payments places this provider in the 80th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$142,822
Medicare patients
642
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$57,777
XdemvyLotilaner12$22,530
MieboPerfluorohexyloctane/Pf12$8,862
Loteprednol Etabonate22$2,635
Prednisolone Acetate60$1,749
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha66$683
Tobramycin-DexamethasoneTobramycin/Dexamethasone20$663
Ofloxacin45$561
Latanoprost64$487
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$168
ErythromycinErythromycin Base14$123
Timolol Maleate13$109
Doxycycline Hyclate12$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$120$57,77748 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$144$22,53012 claims
Bausch & Lomb Americas Inc.Miebo$514$8,86212 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$19$2,63522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →